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Ascertaining invasive breast cancer cases; the validity of administrative and self-
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Abstract 
Background: Statutory State-based cancer registries are considered the ‘gold standard’ for researchers 
identifying cancer cases in Australia, but research using self-report or administrative health datasets (e.g. 
hospital records) may not have linkage to a Cancer Registry and need to identify cases. This study 
investigated the validity of administrative and self-reported data compared with records in a State-wide 
Cancer Registry in identifying invasive breast cancer cases. Methods: Cases of invasive breast cancer 
recorded on the New South Wales (NSW) Cancer Registry between July 2004 and December 2008 (the 
study period) were identified for women in the 45 and Up Study. Registry cases were separately compared 
with suspected cases ascertained from: i) administrative hospital separations records; ii) outpatient 
medical service claims; iii) prescription medicines claims; and iv) the 45 and Up Study baseline survey. 
Ascertainment flags included diagnosis codes, surgeries (e.g. lumpectomy), services (e.g. radiotherapy), 
and medicines used for breast cancer, as well as self-reported diagnosis. Positive predictive value (PPV), 
sensitivity and specificity were calculated for flags within individual datasets, and for combinations of 
flags across multiple datasets. Results: Of 143,010 women in the 45 and Up Study, 2039 (1.4%) had an 
invasive breast tumour recorded on the NSW Cancer Registry during the study period. All of the breast 
cancer flags examined had high specificity (>97.5%). Of the flags from individual datasets, hospital-
derived ‘lumpectomy and diagnosis of invasive breast cancer’ and ‘(lumpectomy or mastectomy) and 
diagnosis of invasive breast cancer’ had the greatest PPV (89% and 88%, respectively); the later having 
greater sensitivity (59% and 82%, respectively). The flag with the highest sensitivity and PPV ≥ 85% was 
'diagnosis of invasive breast cancer' (both 86%). Self-reported breast cancer diagnosis had a PPV of 50% 
and sensitivity of 85%, and breast radiotherapy had a PPV of 73% and a sensitivity of 58% compared with 
Cancer Registry records. The combination of flags with the greatest PPV and sensitivity was 
‘(lumpectomy or mastectomy) and (diagnosis of invasive breast cancer or breast radiotherapy)’ (PPV and 
sensitivity 83%). Conclusions: In the absence of Cancer Registry data, administrative and self-reported 
data can be used to accurately identify cases of invasive breast cancer for sample identification, 
removing cases from a sample, or risk adjustment. Invasive breast cancer can be accurately identified 
using hospital-derived diagnosis alone or in combination with surgeries and breast radiotherapy. 
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Ascertaining invasive breast cancer cases; the
validity of administrative and self-reported data
sources in Australia
Anna Kemp1,2*, David B Preen1, Christobel Saunders3, C D’Arcy J Holman4, Max Bulsara5, Kris Rogers6
and Elizabeth E Roughead7
Abstract
Background: Statutory State-based cancer registries are considered the ‘gold standard’ for researchers identifying
cancer cases in Australia, but research using self-report or administrative health datasets (e.g. hospital records) may
not have linkage to a Cancer Registry and need to identify cases. This study investigated the validity of
administrative and self-reported data compared with records in a State-wide Cancer Registry in identifying invasive
breast cancer cases.
Methods: Cases of invasive breast cancer recorded on the New South Wales (NSW) Cancer Registry between July
2004 and December 2008 (the study period) were identified for women in the 45 and Up Study. Registry cases
were separately compared with suspected cases ascertained from: i) administrative hospital separations records;
ii) outpatient medical service claims; iii) prescription medicines claims; and iv) the 45 and Up Study baseline survey.
Ascertainment flags included diagnosis codes, surgeries (e.g. lumpectomy), services (e.g. radiotherapy), and
medicines used for breast cancer, as well as self-reported diagnosis. Positive predictive value (PPV), sensitivity and
specificity were calculated for flags within individual datasets, and for combinations of flags across multiple
datasets.
Results: Of 143,010 women in the 45 and Up Study, 2039 (1.4%) had an invasive breast tumour recorded on the
NSW Cancer Registry during the study period. All of the breast cancer flags examined had high specificity (>97.5%).
Of the flags from individual datasets, hospital-derived ‘lumpectomy and diagnosis of invasive breast cancer’ and
‘(lumpectomy or mastectomy) and diagnosis of invasive breast cancer’ had the greatest PPV (89% and 88%,
respectively); the later having greater sensitivity (59% and 82%, respectively). The flag with the highest sensitivity
and PPV ≥ 85% was 'diagnosis of invasive breast cancer' (both 86%). Self-reported breast cancer diagnosis had a
PPV of 50% and sensitivity of 85%, and breast radiotherapy had a PPV of 73% and a sensitivity of 58% compared
with Cancer Registry records. The combination of flags with the greatest PPV and sensitivity was ‘(lumpectomy or
mastectomy) and (diagnosis of invasive breast cancer or breast radiotherapy)’ (PPV and sensitivity 83%).
Conclusions: In the absence of Cancer Registry data, administrative and self-reported data can be used to
accurately identify cases of invasive breast cancer for sample identification, removing cases from a sample, or risk
adjustment. Invasive breast cancer can be accurately identified using hospital-derived diagnosis alone or in
combination with surgeries and breast radiotherapy.
Keywords: 45 and up study, Sensitivity, Specificity, Positive predictive value, Lumpectomy, Mastectomy,
Radiotherapy, Hospital diagnosis, Tamoxifen, Anastrazole, Self-report
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Background
Routinely-collected and self-reported health data are in-
creasingly used to identify health status and service use in
research. In Australia, State-based statutory cancer regis-
tries are considered the ‘gold standard’ for identifying
breast cancer cases for research purposes and in recent
years these data have been linked to other routinely-
collected datasets for research [1-3].
Since December 2008, delays in release of mortality data
from the Australian Bureau of Statistics have prevented
the New South Wales (NSW) Cancer Registry from releas-
ing data [4]. Consequently, the gold-standard dataset for
identifying breast cancer in NSW has been inaccessible
from 2009 onward and cancer researchers cannot ascertain
cases from this source. Aside from these recent Australian
issues, researchers in many countries face lengthy delays,
cost or political barriers to accessing linked, routinely-
collected datasets, which are often held by separate custo-
dians and cover different jurisdictions [5-8]. Researchers
who only have access to single datasets (e.g. hospital
records), or specified packages of automatically linked
datasets (e.g. English national hospital and death records
[9], Australian medical service and prescription claims
linked with NSW 45 and Up Study [10]) may want to iden-
tify cases of breast cancer without linkage to a Cancer
Registry.
The aim of this study was to determine whether inci-
dent cases of invasive breast cancer can be accurately
ascertained through a range of routinely-collected ad-
ministrative and self-reported health datasets, with




The study sample was selected from participants enrolled
in the 45 and Up Study; a cohort of approximately
267,000 adults aged ≥45 years residing in NSW [10]. Parti-
cipants in this study provided demographic, lifestyle and
health information upon joining the study and consented
to having their routinely-collected health data linked and
analysed for research purposes [11]. Baseline information
for the 45 and Up Study cohort are already linked to med-
ical service claims and pharmaceuticals publically-
subsided by the Australian government. These datasets
are now being used for many epidemiological studies e.g.
[12-14]. Researchers can also apply to have these records
linked to other NSW and national datasets on a project-
by-project basis. Detailed information regarding the estab-
lishment and recruitment for the 45 and Up Study are
described elsewhere [10]. The present study included
143,010 women recruited between January 2006 and April
2009, who had completed breast cancer-related items in
the baseline survey of the 45 and Up Study.
Ascertaining cases using the gold standard
The NSW Cancer Registry contains, by statutory require-
ment, records of all cancers diagnosed or treated in NSW
[15,16]. The Cancer Registry was considered the ‘gold
standard’ source for cancer identification in this study.
Cases were defined as women with a diagnosis of invasive
breast cancer listed on the NSW Cancer Registry during
the study period; 1 July 2004 to 31st December 2008. Codes
used to identify cases were International Classification of
Diseases version 10 with Australian modifications (ICD-
10-AM) C50.0-C50.9 [17]. Participants with no registry
record during the study period were considered non-cases.
Data sources and linkage
We accessed unit-record linked data from: i) the 45 and
Up Study baseline survey, ii) NSW Admitted Patient
Data Collection; iii) Medicare Benefits Schedule (MBS)
claims; and iv) Pharmaceutical Benefits Scheme (PBS)
claims. All data linkage was conducted by the NSW
Centre for Health Record Linkage [18] and researchers
were provided with de-identified data only.
Ascertaining cases using other datasets
Hospital diagnosis ascertainment flags were identified
through the NSW Admitted Patient Data Collection.
This dataset captures all admissions to public and pri-
vate hospitals in the State of NSW. As with the Cancer
Registry, we identified participants with a principal in-
patient diagnosis of invasive breast cancer using ICD-10-
AM codes C50.0-C50.9. Suspected cases flagged by in-
patient diagnosis were defined as true positives if they oc-
curred within three months of the Cancer Registry date
of diagnosis. Flags for breast cancer surgeries were also
identified from hospital data. We used ICD-10-AM pro-
cedure codes to identify mastectomy (31518–00, 31518–
01, 31524–00, 31524–01), and excision of malignant
breast lump (lumpectomy) (31500–00, 31500-01, 31503-00,
31503-01, 31506-00, 31506-01, 31509-00, 31509-01, 31512-
00, 31512-01) [17]. Suspected cases flagged by surgeries
occurring within three months of the Cancer Registry date
of diagnosis were considered to be true positives.
Flags for breast radiotherapy and prescription medicines
were identified through the MBS and PBS datasets. The
MBS is a claims database which captures medical services
subsidised by the Australian Federal Government for all
Australian citizens [19]. As with the MBS, the PBS is a na-
tional scheme covering all Australian citizens [20]. Breast
radiotherapy is conducted on an outpatient basis in NSW
and was not detected in the hospital dataset. We identified
claims for breast radiotherapy using MBS codes 15221,
15236, 15251, and 15266 [21]. We identified claims for
dispensings of prescribed medicines used to treat breast
cancer using PBS codes. These datasets captured the date
of service for radiotherapy and dispensing of medicines.
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These medicines included selective oestrogen reuptake inhi-
bitors (tamoxifen 2109B, 2110C and toremifene 8216K),
aromatase inhibitors (anastrozole 8179L, exemestane
8506Q, letrozole 8245Y); and other breast cancer ther-
apies (goserelin 1452M; trastuzumab 4632T, 4639E,
4650R, 4703M, 7264H, 7265J, 7266K, 7267L; lapatinib
9148L; 500 mg preparations of medroxyprogesterone
2728N) [22]. All these therapies are only subsidized for
use in women breast cancer. Only 500 mg preparations of
medroxyprogesterone were included because lower dose
preparations are subsidised for indications other than
breast cancer in Australia [23]. Suspected cases of inva-
sive breast cancer flagged by breast radiotherapy or the
specified medicines were considered to be true positives
if these services were provided within 12 months of the
Cancer Registry date of diagnosis. The follow up periods
for diagnosis, surgery, radiotherapy and prescription
medicines vary and were selected to allow for the usual
delays in treatment after diagnosis and were determined
from sensitivity analysis examining different follow up
periods (Additional file 1: Sensitivity analyses).
Process for comparing self-reported diagnosis with the
cancer registry
Self-reported diagnosis of breast cancer was identified
from the 45 and Up Study baseline survey. Recruitment to
the study and completion of the baseline survey com-
menced in January 2006, making this the latest date where
all participants would uniformly have the opportunity to
self-report a diagnosis of breast cancer. Therefore, self-
reports were only compared against cases in the Cancer
Registry for the period 1 July 2004 to 31st December 2005.
The baseline survey asked participants to indicate their
current age in years and months; whether a doctor had
ever told them they had breast cancer (yes/no) and, if
yes, their age in years at diagnosis. We then calculated
the 12 month period in which the participant was the
age they reported being at diagnosis. For example, a
woman aged 72 years and 4 months when recruited to
the study on 19th August 2008 and reporting a cancer
diagnosis at age 68 would have a proxy ‘diagnosis year’
from April 2004 to March 2005. A true positive was
defined as a self-reported diagnosis year overlapping the
period July 2004-December 2005, and a Cancer Registry
date of diagnosis during this period (see Figure 1, Parti-
cipants A and B). A false positive was defined as occur-
ring when the reported diagnosis year overlapped the
period July 2004-December 2005 but no Cancer Registry
record was found for the period (Participants C and D).
A true negative was defined as occurring when the par-
ticipant did not report a breast cancer diagnosis or
reported a diagnosis year that did not overlap the period,
and no Cancer Registry record was found for the period
(Participants E and F). A false negative was defined as
occurring when a participant did not report a diagnosis
of breast cancer or reported a diagnosis year which did
not overlap with the period and a Cancer Registry record
was found for the period (Participants G and H).
Statistical analyses
Breast cancer flags drawn from individual datasets were
compared against the Cancer Registry for PPV, sensitiv-
ity, and specificity (see Table 1) [24,25]. Researchers will
prioritise these indicators differently depending on their
Figure 1 Possible relationships between the study period, diagnosis date recorded on the Cancer Registry, and the diagnosis year
reported by participants.
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reason for identifying cases (e.g. to define a sample, ex-
clude cases from a sample, or for risk adjustment). We
sought to identify flags with high PPV (≥85%) and within
that, the greatest sensitivity. We intend to use these flags
to identify a sample of women with invasive breast can-
cer for future studies.
To determine if combinations of flags improved PPV,
sensitivity or specificity, clinically meaningful combina-
tions of flags were determined in consultation with a
breast cancer surgeon and medical oncologist. These com-
binations of flags (as described in Table 2) were derived
from the commonly utilised combination of 45 and Up
Study baseline, MBS and PBS data; and from all of the
available datasets (hospital, 45 and Up Study baseline data,
MBS and PBS data). These combination flags were also
assessed against the Cancer Registry for PPV, sensitivity
and specificity. Additional sensitivity analyses were under-
taken to determine how many ‘false reports’ of breast can-
cer on the 45 and Up Study baseline survey were recorded
cases on the Cancer Registry, but with incorrectly reported
age at diagnosis. All analyses were conducted in IBM SPSS
version 19.0.
Ethics approval
Ethical approval for this project was received from The
University of Western Australia (WA) Human Research
Ethics Committee (approval RA/4/1/4589) and the NSW
Population and Health Services Research Ethics Committee
(approval HREC/11/CIPHS/35).
Results
Of the 143,010 women in the 45 and Up Study cohort,
2039 (1.4%) had an invasive breast tumour recorded on
the NSW Cancer Registry during the study period. Of
these, 681 (33.4%) occurred between 1 July 2004 and
31st December 2005, and this subgroup was compared
against self-reported breast cancer for the cohort.
Breast cancer flags from individual datasets
Table 1 shows the number of suspected cases flagged
within each of the datasets examined. All of the breast
cancer flags had high specificity (>98.5%). Self-reported
diagnosis of breast cancer had a PPV of only 50% com-
pared with the Cancer Registry; however the sensitivity
was 85%. PPV and sensitivity of the hospital diagnosis of
invasive breast cancer were both 86% and for lumpec-
tomy 52% and 61%, respectively. Hospital-derived mast-
ectomy had a higher PPV of 71% against the Cancer
Registry but lower sensitivity (33%). When considering
combinations of flags within hospital data, the one with
the highest sensitivity for a flag with PPV over 85% was
‘(lumpectomy or mastectomy) and diagnosis of invasive
breast cancer’. PPV and sensitivity for this combination
were 88% and 82%, respectively. Among the flags from
medical service and prescription medicine claims, breast
Table 1 Validity of breast cancer flags in individual datasets compared with the Cancer Registry, July 2004-December 2008
Data set Breast cancer flags Positive predictive
value
Sensitivity Specificity





Diagnosis3 of invasive breast cancer 85.9% 86.1% 99.8%
Lumpectomy 52.0% 60.7% 99.2%
Mastectomy 70.8% 32.6% 99.8%
Lumpectomy OR mastectomy 56.4% 84.4% 99.1%
Lumpectomy AND diagnosis of invasive breast cancer 89.0% 59.1% 99.9%
Mastectomy AND diagnosis of invasive breast cancer 85.4% 31.8% 99.1%
(Lumpectomy or mastectomy) AND diagnosis of invasive breast
cancer
87.7% 82.3% 99.8%
(Lumpectomy or mastectomy) OR diagnosis of invasive breast
cancer
56.5% 88.2% 99.0%
Mastectomy OR diagnosis of invasive breast cancer 79.7% 87.6% 99.7%
Lumpectomy OR diagnosis of invasive breast cancer 58.2% 87.6% 99.1%
Medicare Benefits Schedule Breast radiotherapy 72.8% 57.6% 99.7%
Pharmaceutical Benefits
Scheme
Dispensed medicine for breast cancer 4 45.5% 65.4% 98.9%
1: Comparison to Cancer Registry was restricted to July 2004-December 2005.
2: Reported cancer with birth-year occurring in or overlapping with the period July 2004-December 2005.
3: Primary diagnosis field.
4: Tamoxifen, toremifene, anastrozole, exemestane, letrozole, goserelin, trastuzumab, lapatinib, and medroxyprogesterone 500 mg.
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radiotherapy had the highest PPV and sensitivity (73%
and 58%, respectively). Use of any medicine for breast
cancer had a PPV of 46% and sensitivity of 65%.
Breast cancer flags from multiple datasets
Combinations of flags derived from the package of 45
and Up Study baseline survey, MBS and PBS datasets
are shown in Table 2. All of the ascertainment flags from
multiple datasets had high specificity (>97.5%). None of
the combinations of flags from these datasets had PPV
>85%; the highest PPV being 80% for the flag combin-
ation ‘breast radiotherapy and a dispensed medicine
(sensitivity 40%). Very high sensitivity was observed for
the flag combination of ‘breast radiotherapy or a dis-
pensed medicine or self-reported diagnosis of breast
cancer' (95%); however PPV was low (27%).
Combinations of flags which included hospital data are
also shown in Table 2. Specificity was above 99.5% for
all the flag combinations. Good PPV (>85%) was found
for several flag combinations including surgeries, hos-
pital diagnosis, breast radiotherapy, dispensed medicines,
or self-reported diagnosis; however sensitivity was lower
(range 29%-71%). The combination of flags with the
highest sensitivity and PPV over 85% was ‘(lumpectomy
or mastectomy) and hospital diagnosis and self-reported
diagnosis)’ (PPV 89%, sensitivity 41%). In contrast to the
flags derived from hospital data alone none of the com-
binations of flags from multiple datasets were found to
have PPV ≥85% and sensitivity above 80%.
A total of 581 women were considered to have ‘falsely’
reported a diagnosis of breast cancer because they had
no record of invasive breast cancer on the Cancer Regis-
try within 12 months of the birth year they reported. Of
these, 399 (69%) were found to have a Cancer Registry
record for invasive breast cancer for an earlier or later
period. These women had misreported their age at diag-
nosis but not their history of diagnosis.
Discussion
We sought to identify flags for invasive breast cancer with
PPV ≥85% and, within that, the greatest sensitivity. Of the
ascertainment flags examined from individual datasets, the
flag meeting these criteria was hospital-derived ‘diagnosis
of invasive breast cancer’. When compared with the gold-
standard Cancer Registry this flag combination had a PPV
and sensitivity both of 86%. In other words, 86% of the
suspected cases identified by this flag were true positives,
and 86% of the cases listed on the Cancer Registry during
the study period were identified by this flag. The addition
of flags from other Australian datasets (i.e. medical service,
prescription claims and survey data) to these hospital-
Table 2 Validity of combinations of breast cancer flags compared with the Cancer Registry, July 2004-December 2008
Breast cancer flags Positive
predictive value
Sensitivity Specificity
45 and Up Study baseline, Medicare Benefits Schedule and Pharmaceutical Benefits Scheme
Breast radiotherapy AND dispensed medicine 80.1% 40.3% 99.9%
Breast radiotherapy OR dispensed medicine1 47.9% 82.7% 98.7%
Breast radiotherapy AND self-reported diagnosis 69.3% 36.1% 99.9%
Breast radiotherapy AND dispensed medicine AND self-reported diagnosis2 72.1% 23.9% 99.9%
(Breast radiotherapy OR dispensed medicine) AND self-reported diagnosis 58.6% 60.4% 99.8%
Breast radiotherapy OR dispensed medicine OR self-reported diagnosis 27.0% 95.3% 97.7%
Admitted Patients Data Collection, 45 and Up Study baseline, Medicare Benefits Schedule and
Pharmaceutical Benefits Scheme
(Lumpectomy or mastectomy) AND diagnosis of invasive breast cancer AND breast radiotherapy 90.1% 47.5% 99.9%
(Lumpectomy or mastectomy) AND diagnosis of invasive breast cancer AND breast radiotherapy AND
dispensed medicine
89.7% 33.7% 99.9%
(Lumpectomy or mastectomy) AND diagnosis of invasive breast cancer AND dispensed medicine 87.8% 55.0% 99.9%
(Lumpectomy or mastectomy) AND (diagnosis of invasive breast cancer OR breast radiotherapy) 83.0% 83.2% 99.8%
(Lumpectomy or mastectomy) AND (diagnosis of invasive breast cancer OR dispensed medicine) 84.1% 83.1% 99.8%
(Lumpectomy or mastectomy) AND (diagnosis of invasive breast cancer OR breast radiotherapy OR
dispensed medicine)
80.5% 83.6% 99.7%
(Lumpectomy or mastectomy) AND diagnosis of invasive breast cancer AND self-reported diagnosis 88.5% 71.1% 99.9%
(Lumpectomy or mastectomy) AND diagnosis of invasive breast cancer AND breast radiotherapy AND
self-reported diagnosis
87.3% 29.4% 99.9%
1: Tamoxifen, toremifene, anastrozole, exemestane, letrozole, goserelin, trastuzumab, lapatinib, and medroxyprogesterone 500 mg.
2: Flag combinations including self-reported diagnosis of breast cancer were compared against the Cancer Registry for the period July 2004 to December 2005.
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derived flags did not results in combinations with both
PPV and sensitivity over 85%.
Researchers working with the combination of Australian
medical service claims, pharmaceutical claims and self-
reported data could most accurately identify cases of inva-
sive breast cancer using the flag combination of ‘breast
radiotherapy and a dispensed medicine’. Around 80% of
cases identified by this flag were true cases, compared with
the gold standard, and this flag identified 40% of the inva-
sive breast cancers recorded on the Cancer Registry dur-
ing the study period. Much higher sensitivity was achieved
with the flag ‘breast radiotherapy or a dispensed medicine
or self-reported diagnoses; however the corresponding
PPV was poor (27%).
To our knowledge, this is the first study to examine the
validity of multiple breast cancer flags from multiple data-
sets against an Australian State Cancer Registry. Such in-
vestigation is important due to the increasing use of
administrative and self-reported data in epidemiological
studies, and with the unavailability of Cancer Registry data
in some jurisdictions. We have used health and medical
records for a large, heterogeneous sample of women for
whom all public and private inpatient diagnoses and sur-
geries, subsidised outpatient procedures and medicines
have been captured.
Some limitations exist which may have implications for
this study. This study was conducted as part of a larger
program of research examining use of endocrine therapies
for invasive breast cancer in Australian clinical practice.
The data we requested from the Cancer Registry were
therefore restricted to invasive breast cancer and did not
include records for ductal carcinoma in situ (DCIS). We
were therefore unable to determine how often false posi-
tive flags were picking up genuine cases of DCIS and how
many were unrelated to breast cancer of any kind. We
examined the validity of various breast cancer flags for
women in the 45 and Up Study who, by definition, are
aged 45 years and over and have consented to their health
records being used for research purposes. The health ser-
vice use of these women may differ from younger women
with breast cancer, or women who do not agree to partici-
pate in cohort studies. Therefore, the PPV, sensitivity and
specificity calculated here for various flags may differ from
those that would be found in whole-of-population studies.
The validity of the flags examined here are impacted by
the proportion of women who move out of NSW between
diagnosis and treatment, as well as those dying prior to
treatment or declining treatment. It may also be that the
validity of the breast cancer flags examined here will
change over time in response to changes in health service
use and medical advancement.
Each of the flags we examined had very high specificity,
which is to be expected given the low prevalence of breast
cancer within the cohort (1.4%). In such a scenario, even a
model which predicted no breast cancer at all would retain
high specificity. Therefore, it is important to examine the
PPV and sensitivity of all predictors. The optimum method
for identifying cases of breast cancer without access to a
Cancer Registry will depend on the type and number of
datasets available and the reason cases need to be identi-
fied. Researchers seeking to exclude possible cases of breast
cancer from their datasets will be most concerned with the
specificity of breast cancer flags. All of the breast cancer
flags we examined in this study, whether derived from indi-
vidual or multiple datasets, had high specificity (>97.5%).
Each of these would be suitable for identifying non-cases
with high accuracy. Researchers wishing to identify any
suspected cases of breast cancer for situations where some
false positives are acceptable, such as risk adjustment,
would likely prioritise flags with high sensitivity. In con-
trast, PPV would likely be most important for researchers
seeking to identify breast cancer cases with the fewest pos-
sible false negatives (e.g. to select an affected cohort) [26].
The sensitivity and specificity of the hospital-derived
flags we calculated are similar to those reported in a
NSW study, which demonstrated the hospital proce-
dures ‘lumpectomy or mastectomy’ identified invasive
breast cancers in the Cancer Registry with high sensitiv-
ity (83%) and specificity (95%) [27]. International studies
have also reported high accuracy for hospital records in
identifying breast cancer [26,28,29]. In an Italian study
of hospital records, the combination of hospital diagno-
sis together with ‘lumpectomy or mastectomy’ accurately
identified the majority of cases on the Cancer Registry
(PPV 91%, sensitivity 85%, specificity 99%) [26].
We found that self-reported diagnosis of breast cancer
correctly identified 50% of invasive breast cancer diagno-
ses to within 12-months of the birth year reported.
While one would expect individuals to self-report diag-
noses such as cancer reliably [30,31], the baseline survey
did not ask woman to differentiate between invasive
breast cancer and DCIS. Women may have accurately
reported a DCIS as a diagnosis of breast cancer, however
our data extract from the Cancer Registry was limited to
invasive tumours so this was not able to be confirmed. In
addition, women may not accurately recall the age at
which they were diagnosed [30-32]. In this study, women
reporting a ‘diagnosis year’ overlapping the period July
2004 to December 2005 but without a Cancer Registry
diagnosis during this period were considered false posi-
tives. A sensitivity analysis indicated that 399 of 581 (69%)
of these ‘false positives’ (according to our definition) did
have a Cancer Registry diagnosis for invasive breast can-
cer, but had incorrectly reported their age at diagnosis.
Conclusion
The Cancer Registry is the gold standard for identifying in-
cident cases of invasive breast cancer in most jurisdictions.
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The findings from this study indicate that other adminis-
trative and self-reported datasets examined can be used to
accurately identify cases of invasive breast cancer when
Cancer Registry data are unavailable. Cases of invasive
breast cancer were most accurately identified by hospital-
derived diagnosis of invasive breast cancer. This flag would
be most suitable for researchers seeking to identify a study
cohort with invasive breast cancer or for risk adjustment
[26]. However, all of the flags examined in this study accur-
ately identified cases without invasive breast cancer, so are
suitable for researchers wishing to exclude cases from
population-based datasets likely to have low prevalence of
breast cancer.
Additional file
Additional file 1: Sensitivity analyses comparing follow-up periods
for selected flags, compared with the Cancer Registry, July 2004-
December 2008.
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